Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethyl-EPA versus placebo in Huntington's disease
2005-002088-98Phase 3Terminated
- Sponsor
- Amarin Corporation plc
- Start
- Aug 2005
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3-acid triglycerides in Huntington disease (HD) (2 arms), sponsored by Amarin Corporation plc. Primary endpoint: Change from baseline in TMS-4 over 6 months. Started Aug 2005; status: terminated.
02
Drugs
omega-3-acid triglycerides
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2005-002088-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002088-98.